How Assistance Works

Streamlining our patient’s specialty pharmacy experience with unmatched full-service convenience

  • 1. Check Your Coverage/Benefits Verification

    Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.

  • 2. Transfer Prescription to AmeriPharma™

    We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.

  • 3. Prior Authorization

    Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.

  • 4. Copay Assistance & Financial Aid

    We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma™ Specialty Care has secured $55 million in financial assistance for our patients.

  • 5. Nursing Care Coordination

    AmeriPharma™ puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.

  • 6. Delivery Coordination

    Medications are always delivered in strict compliance with the specific requirements for shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.

What Is Ultomiris?

Ultomiris (generic name: ravulizumab) is a type of medication called monoclonal antibodies, similar to antibodies that our bodies make to protect us when an unwanted substance enters our bodies. In the case of Ultomiris, the antibody is humanized, which means its protein sequences have been modified to increase its similarity to those produced naturally in our bodies, making it safe for human administration.

Serious meningococcal infection risk:

Ultomiris has a US Black Box Warning due to the possibility of causing serious meningococcal infection:

“Life-threatening meningococcal infections/sepsis have occurred in patients treated with Ultomiris. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.

Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Ultomiris, unless the risks of delaying Ultomiris therapy outweigh the risk of developing a meningococcal infection.

Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

Ultomiris is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).”

What is Ultomiris Used For?

Ultomiris is used for the treatment of:

  • Atypical hemolytic uremic syndrome (aHUS), which is a disease that mainly affects kidney function. There is no specific age group for when this condition may occur. It can cause blood clotting to happen abnormally in the small blood vessels of the kidneys, which in turn could cause serious medical problems if blood flow becomes restricted or blocked.
  • Myasthenia gravis (MG), which is a chronic autoimmune disorder in which the body’s own antibodies start attacking and destroying the connection that is responsible for communication between nerves and muscles. This results in weakness of the skeletal muscles. Myasthenia gravis generally affects voluntary muscles of the body, mainly those controlling the limbs, mouth, throat, and eyes.
  • Paroxysmal nocturnal hemoglobinuria (PNH), which is a rare, acquired, life-threatening disease of the blood. The disease is characterized by premature destruction of red blood cells, blood clots, and impaired bone marrow function. PNH is closely related to aplastic anemia.

Copay and Financial Assistance

AmeriPharma™ Specialty Care alleviates financial burdens for patients and their families

  • Advanced software locates funding sources to match you with top-dollar foundation programs

  • One of our copay assistance specialists will assist with the application process

  • Automatic updates will be sent to you and your physician on the status of the funding

Directions for Use

Ultomiris dosing is based on body weight.

Treatment starts with a loading dose, then after 2 weeks, a maintenance dose is administered and then repeated every 8 weeks (4 weeks in some cases with pediatric patients).

Ultomiris is first diluted, then administered intravenously using a catheter that is inserted into the vein. Infusion is done over 36 minutes to 3.5 hours (depending on the dose to be given and the patient’s body weight). Infusions are followed by a 1-hour monitoring time for any signs or symptoms of an infusion reaction.

Ultomiris is only available through a REMS program due to the increased risk of life-threatening meningococcal infections, which can lead to death. Patients must receive the meningococcal vaccine at least 2 weeks before the first dose if they are not already vaccinated.

Ultomiris Side Effects

  •  Diarrhea
  • Headache
  • Upper respiratory tract infection
  • Abdominal pain
  • Urinary tract infection
  • Infusion-related reaction
  • Dizziness
  • Joint stiffness
  • Back pain
  • Pain in the arms or legs
  • Fever
  • Antibody development
  • Infection: meningococcal infection, sepsis
  • Hyperthermia (an abnormally high body temperature, which needs immediate treatment)
  • Hypersensitivity/anaphylaxis

Insurances Accepted

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.

  • Medicaid logo

Get Started in Minutes

Fill out your information and one of our specialists will call you ASAP.

How Much Can You Save?

Speak with a copay assistance specialist

(877) 778-0318